{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,13]],"date-time":"2026-04-13T15:41:23Z","timestamp":1776094883975,"version":"3.50.1"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["neurology.org"],"crossmark-restriction":true},"short-container-title":["Neurology"],"published-print":{"date-parts":[[1996,4]]},"DOI":"10.1212\/wnl.46.4.965","type":"journal-article","created":{"date-parts":[[2012,5,13]],"date-time":"2012-05-13T13:19:17Z","timestamp":1336915157000},"page":"965-968","update-policy":"https:\/\/doi.org\/10.1212\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":68,"title":["A controlled trial of deprenyl in children with Tourette's syndrome and attention deficit hyperactivity disorder"],"prefix":"10.1212","volume":"46","author":[{"given":"A.","family":"Feigin","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Kurlan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.P.","family":"McDermott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Beach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Dimitsopulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.A.","family":"Brower","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Chapieski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"K.","family":"Trinidad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P.","family":"Como","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Jankovic","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"276","reference":[{"key":"e_1_3_1_2_2","unstructured":"Jankovic J. The neurology of tics. In: Marsden CD Fahn S eds. Movement disorders 2. London: Butterworths Scientific 1987:383-405."},{"key":"e_1_3_1_3_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.39.1.1"},{"key":"e_1_3_1_4_2","first-page":"4","volume":"5","year":"1989","unstructured":"Singer HS, Rosenberg LA. Development of behavioral and emotional problems in Tourette's syndrome. Pediatr Neurol 1989;5:41-44.","journal-title":"Pediatr Neurol"},{"key":"e_1_3_1_5_2","first-page":"6","volume":"29","year":"1990","unstructured":"Jacobvitz D, Sroufe A, Stewart M, Leffert N. Treatment of attentional and hyperactivity problems in children with sympathomimetic drugs: a comprehensive review. J Am Acad Child Adolesc Psychiatry 1990;29:677-688.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"e_1_3_1_6_2","first-page":"6","volume":"26","year":"1987","unstructured":"Grad L, Pelcovitz D, Olson M, et al. Obsessive-compulsive symptomatology in children with Tourette's syndrome. J Am Acad Child Adolesc Psychiatry 1987;26:69-73.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"e_1_3_1_7_2","first-page":"5","volume":"14","year":"1987","unstructured":"Jankovic J, Rohaidy H. Motor, behavioral and pharmacologic findings in Tourette's syndrome. Can J Neurol Sci 1987;14:541-546.","journal-title":"Can J Neurol Sci"},{"key":"e_1_3_1_8_2","first-page":"4","volume":"51","year":"1990","unstructured":"Comings DE, Himes JA, Comings BG. An epidemiologic study of Tourette's syndrome in a single school district. J Clin Psychiatry 1990;51:463-469.","journal-title":"J Clin Psychiatry"},{"key":"e_1_3_1_9_2","first-page":"4","volume":"37","year":"1985","unstructured":"Comings DE, Comings BG. Tourette syndrome: clinical and psychological aspects of 250 cases. Am J Hum Genet 1985;37:435-450.","journal-title":"Am J Hum Genet"},{"key":"e_1_3_1_10_2","first-page":"1","volume":"36","year":"1989","unstructured":"Stevenson RD, Wolraich MI. Stimulant medication therapy in the treatment of children with attention deficit hyperactivity disorder. Clin Pharmacol 1989;36:1183-1195.","journal-title":"Clin Pharmacol"},{"key":"e_1_3_1_11_2","first-page":"2","volume":"11","year":"1990","unstructured":"Gadow KD, Sverd J. Stimulants for ADHD in child patients with Tourette's syndrome: the issue of relative risk. J Dev Behav Pediatr 1990;11:269-271.","journal-title":"J Dev Behav Pediatr"},{"key":"e_1_3_1_12_2","first-page":"4","volume":"15","year":"1992","unstructured":"Robertson MM, Eapen V. Pharmacologic controversy of CNS stimulants in Gilles de la Tourette's syndrome. Clin Neuropharmacol 1992;15:408-425.","journal-title":"Clin Neuropharmacol"},{"key":"e_1_3_1_13_2","first-page":"6","volume":"34","year":"1984","unstructured":"Jankovic J, Glaze DG, Frost JD. Effect of tetrabenazine on tics and sleep of Gilles de la Tourette's syndrome. Neurology 1984;34:688-692.","journal-title":"Neurology"},{"key":"e_1_3_1_14_2","first-page":"3","volume":"12","year":"1982","unstructured":"Singer HS, Butler IJ, Tune LE, et al. Dopaminergic dysfunction in Tourette syndrome. Arch Neurol 1982;12:361-366.","journal-title":"Arch Neurol"},{"key":"e_1_3_1_15_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.28.1.1"},{"key":"e_1_3_1_16_2","first-page":"2","volume":"19","year":"1993","unstructured":"Stern GM, Lees AJ, Hardie R, Sandler M. Clinical and pharmacological aspects of (-)deprenyl treatment in Parkinson's disease. Mob Probl Pharmacopsychiat 1993;19:215-219.","journal-title":"Mob Probl Pharmacopsychiat"},{"key":"e_1_3_1_17_2","first-page":"2","volume":"50","year":"1993","unstructured":"Jankovic J. Deprenyl in attention deficit associated with Tourette's syndrome. Arch Neurol 1993;50:286-288.","journal-title":"Arch Neurol"},{"key":"e_1_3_1_18_2","doi-asserted-by":"publisher","DOI":"10.1207\/s15374424jccp2001_1"},{"key":"e_1_3_1_19_2","unstructured":"Achenbach TM Edelbrock CS. Manual for the Child Behavioral Checklist and revised behavioral profile. Burlington VT: University of Vermont Department of Psychiatry 1983."},{"key":"e_1_3_1_20_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-7138(09)60593-8"},{"key":"e_1_3_1_21_2","first-page":"1","volume":"46","year":"1981","unstructured":"Goodwin WK, Price LM, Rasmussen SA, et al. The Yale-Brown obsessive compulsive scale. I. development, use, and reliability. Arch Gen Psychiatry 1981;46:1006-1011.","journal-title":"Arch Gen Psychiatry"},{"key":"e_1_3_1_22_2","first-page":"5","volume":"28","year":"1989","unstructured":"Leckman JF, Towbin KE, Ort SI, et al. The Yale global tic severity scale (YGTSS): initial testing of a clinician-rated scale of tic severity. J Am Acad Child Adolesc Psychiatry 1989;28:566-573.","journal-title":"J Am Acad Child Adolesc Psychiatry"},{"key":"e_1_3_1_23_2","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.37.1.1"},{"key":"e_1_3_1_24_2","doi-asserted-by":"crossref","unstructured":"Jones B Kenward MG. Design and analysis of cross-over trials. London: Chapman and Hall 1989.","DOI":"10.4324\/9780203009277"},{"key":"e_1_3_1_25_2","unstructured":"Senn S. Cross-over trials in clinical research. New York: Wiley 1993."},{"key":"e_1_3_1_26_2","unstructured":"Physicians' desk reference 49th ed. Montvale NJ: Medical Economics Data Production Company 1995:419 2362."},{"key":"e_1_3_1_27_2","first-page":"7","volume":"56","year":"1994","unstructured":"Heinonen EH, Antilla MI, Lammintausta RAS. Pharmacokinetic aspects of l-deprenyl (selegiline) and its metabolites. Clin Pharm Ther 1994;56:742-749.","journal-title":"Clin Pharm Ther"},{"key":"e_1_3_1_28_2","first-page":"9","volume":"42","year":"1985","unstructured":"Zametkin A, Rapaport JL, Murphy DL, et al. Treatment of hyperactive children with monoamine oxidase inhibitors. I. clinical efficacy. Arch Gen Psychiatr 1985;42:962-966.","journal-title":"Arch Gen Psychiatr"},{"key":"e_1_3_1_29_2","doi-asserted-by":"crossref","unstructured":"Elia J. Use of moclobemide in children with attention deficit hyperactivity disorder. Psychopharmacology 1992;106(Suppl):S134-136.","DOI":"10.1007\/BF02246258"}],"container-title":["Neurology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.neurology.org\/doi\/pdfdirect\/10.1212\/WNL.46.4.965","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T13:37:18Z","timestamp":1711546638000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.neurology.org\/doi\/10.1212\/WNL.46.4.965"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[1996,4]]},"references-count":28,"journal-issue":{"issue":"4","published-print":{"date-parts":[[1996,4]]}},"alternative-id":["10.1212\/WNL.46.4.965"],"URL":"https:\/\/doi.org\/10.1212\/wnl.46.4.965","relation":{},"ISSN":["0028-3878","1526-632X"],"issn-type":[{"value":"0028-3878","type":"print"},{"value":"1526-632X","type":"electronic"}],"subject":[],"published":{"date-parts":[[1996,4]]}}}